News

Royalty Pharma published press releases by date and/or category

Royalty Pharma to Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024

NEW YORK, NY, January 30, 2024 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2023 financial results on Thursday, February 15, 2024 before the U.S. financial markets open.

Royalty Pharma Announces Dividend Increase

NEW YORK, NY, January 19, 2024 – Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2024 of $0.21 per Class A share, reflecting a 5% increase in the company’s quarterly dividend over the previous quarter’s dividend.

Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference

NEW YORK, NY, January 8, 2024 - Royalty Pharma plc (Nasdaq: RPRX) today provided an update on its business performance, including recent key accomplishments, and the full year 2023 outlook for Portfolio Receipts.

Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference

NEW YORK, NY, November 27, 2023 - Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 6^th Annual HealthCONx Conference on November 28, 2023 at 3:00 p.m. ET.

Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine LAI Program

NEW YORK, NY, and TEL AVIV, ISRAEL, November 13, 2023 - Royalty Pharma plc (Nasdaq: RPRX) and Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA)

Royalty Pharma Reports Third Quarter 2023 Results

NEW YORK, NY, November 08, 2023 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2023 and raised full-year 2023 guidance for Adjusted Cash Receipts(1) (a non-GAAP financial measure).

Royalty Pharma Announces Agreement to Purchase up to $1.5 Billion of PTC Therapeutics’ Royalty on Evrysdi

NEW YORK, NY, October 19, 2023 - Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche’s Evrysdi for $1.0 billion upfront.

Royalty Pharma Declares Fourth Quarter 2023 Dividend

NEW YORK, NY, October 16, 2023 - The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2023 of $0.20 per Class A ordinary share.

Royalty Pharma To Announce Third Quarter 2023 Financial Results On November 8, 2023

NEW YORK, NY, October 11, 2023 - Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2023 financial results on Wednesday, November 8, 2023 before the U.S. financial markets open.

Royalty Pharma Appoints Eric Schneider as Chief Technology Officer

NEW YORK, NY, September 21, 2023 – Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Eric Schneider as Senior Vice President, Chief Technology Officer. Eric will also join Royalty Pharma’s Senior Leadership Committee.